Advertisement

Current Breast Cancer Reports

, Volume 2, Issue 1, pp 53–58 | Cite as

Lymphedema: How Do We Diagnose and Reduce the Risk of This Dreaded Complication of Breast Cancer Treatment?

  • Michael J. Bernas
  • Robert L. Askew
  • Jane M. Armer
  • Janice N. CormierEmail author
Article

Abstract

Lymphedema is an under-recognized, progressive, life-long condition estimated to impact 2-3 million people in the United States. The incidence of breast cancer related lymphedema varies greatly in the literature largely due to different measurement techniques, competing thresholds for defining lymphedema, and variation in length of follow-up. Multiple imaging techniques have become useful for diagnosis. Lymphoscintigraphy is one of the most commonly used, as it can identify pathways of lymphatic drainage, quantify extent of dermal backflow, and help determine functional and morphologic changes in the lymphatic system. Early detection and intervention hold the greatest promise of reducing the incidence of lymphedema. Health care providers involved with cancer patients need to become more educated about lymphedema, aware of current risk-reduction practices, and familiar with methods of diagnosis and assessment, so that patients with early swelling can be referred to lymphedema treatment specialists at a time when treatment is more effective.

Keywords

Lymphedema Breast cancer 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Passik SD, McDonald MV: Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer 1998, 83(Suppl 12):2817–2820.CrossRefPubMedGoogle Scholar
  2. 2.
    Petrek JA, Heelan MC: Incidence of breast carcinoma-related lymphedema. Cancer 1998, 83(Suppl 12):2776–2781.CrossRefPubMedGoogle Scholar
  3. 3.
    Meek AG: Breast radiotherapy and lymphedema. Cancer 1998, 83(Suppl 12):2788–2797.CrossRefPubMedGoogle Scholar
  4. 4.
    Rockson SG: Precipitating factors in lymphedema: myths and realities. Cancer 1998, 83(Suppl 12):2814–2816.CrossRefPubMedGoogle Scholar
  5. 5.
    Seer Cancer Statistics Review, 1975-2006. Available at http://seer.cancer.gov/csr/1975_2006/. Accessed November 24, 2009.
  6. 6.
    Ahmed RL, Prizment A, Lazovich D, et al.: Lymphedema and quality of life in breast cancer survivors: the Iowa Women’s Health Study. J Clin Oncol 2008, 26:5689–5696.CrossRefPubMedGoogle Scholar
  7. 7.
    Norman SA, Localio AR, Potashnik SL, et al.: Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009, 27:390–397.CrossRefPubMedGoogle Scholar
  8. 8.
    Shih YC, Xu Y, Cormier JN, et al.: Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol 2009, 27:2007–2014.CrossRefPubMedGoogle Scholar
  9. 9.
    Morgan PA, Franks PJ, Moffatt CJ: Health-related quality of life with lymphoedema: a review of the literature. Int Wound J 2005, 2:47–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Engel J, Kerr J, Schlesinger-Raab A, et al.: Predictors of quality of life of breast cancer patients. Acta Oncol 2003, 42:710–718.CrossRefPubMedGoogle Scholar
  11. 11.
    Wilson RW, Hutson LM, Vanstry D: Comparison of 2 quality-of-life questionnaires in women treated for breast cancer: the RAND 36-Item Health Survey and the Functional Living Index-Cancer. Phys Ther 2005, 85:851–860.PubMedGoogle Scholar
  12. 12.
    Coen JJ, Taghian AG, Kachnic LA, et al.: Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 2003, 55:1209–1215.PubMedGoogle Scholar
  13. 13.
    Deutsch M, Flickinger JC: Arm edema after lumpectomy and breast irradiation. Am J Clin Oncol 2003, 26:229–231.CrossRefPubMedGoogle Scholar
  14. 14.
    Meek AG: Breast radiotherapy and lymphedema. Cancer 1998, 83 (Suppl 12):2788–2797.CrossRefPubMedGoogle Scholar
  15. 15.
    Ozaslan C, Kuru B: Lymphedema after treatment of breast cancer. Am J Surg 2004, 187:69–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Wilke LG, McCall LM, Posther KE, et al.: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006, 13:491–500.CrossRefPubMedGoogle Scholar
  17. 17.
    Williams CJ: Lymphoedema: estimating the size of the problem. Palliative Med 2005, 19:300–313.CrossRefGoogle Scholar
  18. 18.
    Pezner RD, Patterson MP, Hill LR, et al.: Arm lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys 1986, 12:2079–2083.PubMedGoogle Scholar
  19. 19.
    Roses DF, Brooks AD, Harris MN, et al.: Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999, 230:194–201.CrossRefPubMedGoogle Scholar
  20. 20.
    Larson D, Weinstein M, Goldberg I, et al.: Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986, 12:1575–1582.PubMedGoogle Scholar
  21. 21.
    Kissin MW, Querci della Rovere G, Easton D, Westbury G: Risk of lymphoedema following the treatment of breast cancer. Br J Surg 1986, 73:580–584.Google Scholar
  22. 22.
    Johansson K, Ohlsson K, Ingvar C, et al.: Factors associated with the development of arm lymphedema following breast cancer treatment: a match pair case-control study. Lymphology 2002, 35:59–71.PubMedGoogle Scholar
  23. 23.
    Kocak Z, Overgaard J: Risk factors of arm lymphedema in breast cancer patients. Acta Oncol 2000, 39:389–392.CrossRefPubMedGoogle Scholar
  24. 24.
    Rockson SG: Addressing the unmet needs in lymphedema risk management. Lymphat Res Biol 2006, 4:42–46.CrossRefPubMedGoogle Scholar
  25. 25.
    Witte CL, Witte MH, Unger EC, et al.: Advances in imaging of lymph flow disorders. Radiographics 2000, 20:1697–1719.PubMedGoogle Scholar
  26. 26.
    Bourgeois P, Leduc O, Leduc A: Imaging techniques in the management and prevention of posttherapeutic upper limb edemas. Cancer 1998, 83(Suppl 12):2805–2813.CrossRefPubMedGoogle Scholar
  27. 27.
    Kramer EL: Lymphoscintigraphy: defining a clinical role. Lymphat Res Biol 2004, 2:32–37.CrossRefPubMedGoogle Scholar
  28. 28.
    Blum KS, Radtke C, Knapp WH, et al.: SPECT-CT: a valuable method to document the regeneration of lymphatics and autotransplanted lymph node fragments. Eur J Nucl Med Mol Imaging 2007, 34:1861–1867.CrossRefPubMedGoogle Scholar
  29. 29.
    Casley-Smith JR: Measuring and representing peripheral oedema and its alterations. Lymphology 1994, 27:56–70.PubMedGoogle Scholar
  30. 30.
    •• Ward L: Is BIS ready for prime time as the gold standard measure? J Lymphoedema 2009, 4:52–56. This review summarizes the the applicability of bioimpedance spectroscopy in the field of lymphedema.Google Scholar
  31. 31.
    Moseley A, Piller N: Reliability of bioimpedance spectroscopy and tonometry after breast conserving cancer treatment. Lymphat Res Biol 2008, 6:85–87.CrossRefPubMedGoogle Scholar
  32. 32.
    Nuutinen J, Ikaheimo R, Lahtinen T: Validation of a new dielectric device to assess changes of tissue water in skin and subcutaneous fat. Physiol Meas 2004, 25:447–454.CrossRefPubMedGoogle Scholar
  33. 33.
    Mayrovitz HN, Davey S, Shapiro E: Localized tissue water changes accompanying one manual lymphatic drainage (MLD) therapy session assessed by changes in tissue dielectric constant inpatients with lower extremity lymphedema. Lymphology 2008, 41:87–92.PubMedGoogle Scholar
  34. 34.
    Bagheri S, Ohlin K, Olsson G, Brorson H: Tissue tonometry before and after liposuction of arm lymphedema following breast cancer. Lymphat Res Biol 2005, 3:66–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Armer JM, Radina ME, Porock D, Culbertson SD: Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 2003, 52:370–379.CrossRefPubMedGoogle Scholar
  36. 36.
    Liljegren G, Holmberg L: Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997, 33:193–199.Google Scholar
  37. 37.
    Schrenk P, Rieger R, Shamiyeh A, Wayand W: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608–614.CrossRefPubMedGoogle Scholar
  38. 38.
    Armer JM, Whitman M: The problem of lymphedema following breast cancer treatment: prevalence, symptoms, and self-management. Lymphology 2002, 35(Suppl):153–159.Google Scholar
  39. 39.
    •• Armer JM, Stewert BR, Shook RP: 30-month post-breast cancer treatment lymphoedema. J Lymphoedema 2009, 4:14–18. This is a large prospective cohort study of breast cancer survivors followed over 30 months with validated objective measures for lymphedema.Google Scholar
  40. 40.
    Fu MR, Axelrod D, Haber J: Breast-cancer-related lymphedema: information, symptoms, and risk-reduction behaviors. J Nurs Scholarsh 2008, 40:341–348.CrossRefPubMedGoogle Scholar
  41. 41.
    Casley-Smith J, Casley-Smith JR, Lymphoedema Association of Australia: Modern Treatment for Lymphoedema, 5th rev. edn. Adelaide, South Australia: Lymphoedema Association of Australia; 1997.Google Scholar
  42. 42.
    Harris SR, Niesen-Vertommen SL: Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol 2000, 74:95–98; discussion 98–99.Google Scholar
  43. 43.
    Ahmed RL, Thomas W, Yee D, Schmitz KH: Randomized controlled trial of weight training and lymphedema in breast cancer survivors. J Clin Oncol 2006, 24:2765–2772.CrossRefPubMedGoogle Scholar
  44. 44.
    Mortimer PS: Managing lymphoedema. Clin Exp Dermatol 1995, 20:98–106.CrossRefPubMedGoogle Scholar
  45. 45.
    Witte MH, Witte CL: Lymphatics and blood vessels, lymphangiogenesis and hemangiogenesis: from cell biology to clinical medicine. Lymphology 1987, 20:257–266.PubMedGoogle Scholar
  46. 46.
    Petrek JA, Pressman PI, Smith RA: Lymphedema: current issues in research and management. CA Cancer J Clin 2000, 50:292–307; quiz 308–311.Google Scholar
  47. 47.
    •• Stout Gergich NL, Pfalzer LA, McGarvey C, et al.: Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008, 112:2809–2819. This is a small prospective study demonstrating the successful treatment of early lymphedema. Subclinical lymphedema is defined in this article.Google Scholar
  48. 48.
    Thompson M, Korourian S, Henry-Tillman R, et al.: A new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007, 14:1890–1895.CrossRefPubMedGoogle Scholar
  49. 49.
    Bedrosian I, Babiera GV, Mittendorf EA, et al.: A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer 2010 (in press).Google Scholar
  50. 50.
    Boccardo FM, Ansaldi F, Bellini C, et al.: Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 2009, 42:1–9.PubMedGoogle Scholar
  51. 51.
    Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM: Physiotherapy after breast cancer surgery: results of a randomised controlled study to minimise lymphoedema. Breast Cancer Res Treat 2002, 75:51–64.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michael J. Bernas
    • 1
  • Robert L. Askew
    • 2
  • Jane M. Armer
    • 3
  • Janice N. Cormier
    • 2
    Email author
  1. 1.Department of SurgeryThe University of ArizonaTucsonUSA
  2. 2.Department of Surgical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Ellis Fischel Cancer Center, Sinclair School of NursingUniversity of MissouriColumbiaUSA

Personalised recommendations